Journal article
Ipilimumab: from preclinical development to future clinical perspectives in melanoma
Future oncology (London, England), Vol.13(7), pp.625-636
03/01/2017
DOI: 10.2217/fon-2016-0385
PMCID: PMC5618953
PMID: 27882779
Abstract
The arsenal for the treatment of metastatic melanoma is limited. A new approach to therapy using checkpoint blockade has improved overall survival in this patient population. Ipilimumab a CTLA-4 monoclonal antibody is a first in class drug that has pioneered this revolution. In this review, the authors provide an account of the different stages that led to the development of ipilimumab, its approval in the clinical setting for the treatment of advanced melanoma and ongoing investigations of combinatorial immune therapy.
Details
- Title: Subtitle
- Ipilimumab: from preclinical development to future clinical perspectives in melanoma
- Creators
- Paul Letendre - HoldenVarun Monga - HoldenMohammed Milhem - HoldenYousef Zakharia - Holden
- Resource Type
- Journal article
- Publication Details
- Future oncology (London, England), Vol.13(7), pp.625-636
- Publisher
- Future Medicine Ltd
- DOI
- 10.2217/fon-2016-0385
- PMID
- 27882779
- PMCID
- PMC5618953
- ISSN
- 1479-6694
- eISSN
- 1744-8301
- Number of pages
- 12
- Grant note
- P30CA086862 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
- Language
- English
- Date published
- 03/01/2017
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359799602771
Metrics
9 Record Views